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Abstract
Objective: The objective of this propensity score-matched, observational cohort 
study was to determine the effectiveness of osteoporosis medication on reducing the 
risk of non-trauma fracture (NTFx) among adults with epilepsy.
Methods: Data from 01/01/2012 to 09/30/2015 was extracted from Optum 
Clinformatics Data Mart. NTFx risk attenuation from 12 months prior to 12 months 
after the individual's index date was examined for each group of adults ≥50 years of 
age as risk ratios (RRs with 95% confidence intervals [CIs]). Groups were stratified 
based on: (1) epilepsy status, as with vs without epilepsy (EP); and (2) if and when 
osteoporosis medication was first prescribed, as new users (treatment naive), con-
sistent users (osteoporosis medication prescribed in pre-index period), and no users. 
Comparison groups were matched 1:1 to EP new users (n = 828/group) for demo-
graphics, glucocorticoid and antiseizure medication, and the Elixhauser comorbidity 
index. Difference-in-difference analysis compared the change in pre- to post-index 
NTFx risk among groups as the ratio of the RR (RRR).
Results: The pre- to post-index NTFx risk at any site was reduced for EP new users 
(RR = 0.49; 95% CI = 0.40-0.61) and EP consistent users (RR = 0.70; 95% CI = 0.38-
0.98), but nonsignificantly elevated for EP no users (RR = 1.39; 95% CI = 0.93-
2.07)—findings were consistent for most sites (eg, vertebral column). EP new users 
had a larger NTFx risk attenuation at any site compared to EP no users (RRR = 0.35; 
95% CI = 0.23-0.54) and EP consistent users (RRR = 0.70; 95% CI = 0.51-0.97). 
EP consistent users had a larger NTFx risk attenuation at any site compared to EP 
no users (RRR = 0.50; 95% CI = 0.32-0.79). The extent of NTFx risk attenuation 
at any site was similar for new users with vs without epilepsy (RRR = 0.99; 95% 
CI = 0.73-1.34) and consistent users with vs without epilepsy (RRR = 0.81; 95% 
CI = 0.55-1.17). There was evidence of site-specific effects (eg, hip).
Conclusion: Osteoporosis medication is associated with a clinically meaningful  
12-month NTFx risk attenuation for adults with epilepsy, especially for those just 
starting osteoporosis medication.
K E Y W O R D S
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1 |  INTRODUCTION
Skeletal fragility is a major problem for individuals with epi-
lepsy across the lifespan. Children with epilepsy have lower 
bone mineral density and an elevated frequency of fractures 
compared to children without epilepsy.1,2 Approximately 
three of four adults with epilepsy have low bone mineral den-
sity or osteoporosis,3,4 leading to an increased risk for frac-
ture.5 Non-trauma fracture (NTFx), an indicator of skeletal 
fragility, is present in one of five adults ≥18 years of age with 
epilepsy, which is 3.2 times higher compared to the general 
adult population without epilepsy.6
Recently, a large cohort study reported that after account-
ing for demographics and several chronic diseases, the ad-
justed rate of 12-month mortality was 70% higher for adults 
with epilepsy that sustained an NTFx as compared to adults 
with epilepsy that did not sustain an NTFx, and 41% higher 
compared to adults without epilepsy that sustained an NTFx.6 
Although the cause and effect has yet to be elucidated, the el-
evated risk of post-NTFx mortality may be driven by the de-
velopment of cardiorespiratory diseases,7–9 which are among 
the leading causes of premature mortality for individuals 
with epilepsy.10–13 Taken together, these new findings could 
suggest a greater post-NTFx disease and survival burden for 
adults with epilepsy, and underscores the importance of max-
imizing skeletal health throughout the lifespan and attenuat-
ing the risk of NTFx in the adult years.
Despite the significant need, there is a dearth of empiri-
cal evidence about the effectiveness of osteoporosis medica-
tion therapy on skeletal health for individuals with epilepsy. 
Lazzari and colleagues14 started to address this knowledge 
gap and performed a 2-year double-blind, randomized place-
bo-controlled study that included male veterans with epilepsy 
who were taking antiseizure medication, had normal calcium 
and vitamin D levels, were not taking glucocorticoid medica-
tion, and did not have osteoporosis at baseline, among other 
exclusion criteria. The authors reported that treatment with 
risedronate—an antiresorptive bisophosphonate agent—im-
proved bone mineral density and reduced the incidence of 
fractures compared to the placebo group.14 Although fun-
damental to the field, the sample size was small (treatment 
group, n = 27; placebo group, n = 26) and may not be gen-
eralizable to the greater population with epilepsy given the 
strict inclusion criteria that often accompanies randomized 
controlled trials. Furthermore, in general, inferences about 
the effectiveness of osteoporosis medication on fracture risk 
attenuation are limited from randomized controlled trials,15 
as they may not represent the heterogeneity observed in clin-
ical settings for medication adherence, patient populations, 
and medication prescriptions. Therefore, the purpose of this 
propensity score-matched, observational cohort study was 
to determine if osteoporosis medication was associated with 
NTFx risk attenuation among adults with epilepsy.
2 |  METHODS
2.1 | Data source
Claims data were ascertained from January 1, 2012 to 
September 30, 2015 from Optum Clinformatics Data Mart 
Database (OptumInsightTM, Eden Prairie, MN, USA). This 
national single private payer administrative claims database 
contains medical and outpatient pharmacy information from 
privately insured or Medicare Advantage beneficiaries in the 
United States and has been described previously in detail.16 
Because data are de-identified, the University Institutional 
Review Board approved this study as non-regulated.
2.2 | Sample selection
All medical conditions were identified using the International 
Classification of Diseases (ICD), Ninth Revision, Clinical 
Modification codes. As there was a national change in report-
ing ICD-9 to ICD-10 codes on October 1, 2015, this study 
ended on September 30, 2015 to limit bias from unknown 
differences in detection of medical conditions.
Individuals were initially considered for this study if they 
were ≥50 years of age, had at least 12 months of continu-
ous enrollment in the pre-index period to ascertain baseline 
data, had at least 12 months of continuous enrollment in the 
post-index period for the outcome, and utilized health care 
services at least 2 days in the pre-index period (to limit de-
tection bias due to lack of clinician interaction). Epilepsy was 
identified by at least one reimbursement inpatient, outpatient, 
or emergency department claim for “epilepsy and recurrent 
seizures” on at least two separate days within the 12-month 
Key points
• Skeletal fragility is a major problem for adults 
with epilepsy; yet the real-world effectiveness of 
pharmacological osteoporosis therapy is not well 
known
• This private claims-based study found that osteo-
porosis medication was associated with risk atten-
uation of non-trauma fractures (NTFx) for adults 
with epilepsy
• The NTFx risk attenuation was present for the ver-
tebral column, hip, lower extremities, and upper 
extremities
• Treatment naive adults with epilepsy had the larg-
est risk attenuation of NTFx
• The extent of NTFx risk attenuation was similar to 
adults without epilepsy
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pre-index period, as described previously.6 The 2+ claim al-
gorithm has a positive predictive value of ~70%-100% for 
epilepsy.17 Reimbursement claims do not contain or reliably 
code information for etiology, type, or duration of epilepsy. 
For example, 46% of this cohort had an “unspecified” ep-
ilepsy condition. Therefore, stratification or statistical ad-
justment for clinically relevant variables pertaining to the 
epilepsy condition was not performed.
The first outpatient pharmacy claim for osteoporosis med-
ication was identified between January 1, 2012 and September 
30, 2014 (to allow 12 months of follow-up for the outcome), 
and included at least one osteoporosis medications, as guided 
by previous studies.18,19 The index date for those prescribed 
an osteoporosis medication on or after January 1, 2013, was 
the date of the first outpatient pharmacy claim for an osteopo-
rosis medication. The index date for those prescribed an oste-
oporosis medication in the calendar year 2012 was January 1, 
2013. The index date for those not prescribed an osteoporosis 
medication was a randomly assigned date within the study 
period.9
The osteoporosis medication groups were categorized as 
“new” and “consistent” users to examine the effect of chro-
nicity of osteoporosis medication exposure. For example, 
new users may have a larger effect on NTFx risk attenua-
tion. New users were defined as individuals who had no out-
patient pharmacy claims for osteoporosis medication in the 
12-month pre-index period and were considered treatment 
naive.19 Consistent users were defined as individuals who 
had one or more outpatient pharmacy claims for osteoporosis 
medication in the 12-month pre-index period.
The sample was categorized into five groups based on the 
status of epilepsy (EP) and osteoporosis medication prescrip-
tion: adults with epilepsy that were (1) new users (EP new 
users), (2) consistent users (EP consistent users), and (3) not 
prescribed osteoporosis medication (EP no users), and adults 
without epilepsy that were (4) new users (w/o EP new users) 
and (5) consistent users (w/o EP consistent users). EP new 
users were the primary group of interest and all other groups 
were considered comparison groups.
2.3 | Fracture
Fracture occurring at the vertebral column, hip (including 
proximal femur), non-proximal femur, tibia or fibula, hu-
merus, ulna or radius, or at an unspecified site that did not 
have corresponding trauma codes (eg, car accident) 7 days 
before to 7 days after the index date of the fracture event was 
defined as an NTFx, as described previously.6,20–22 All other 
fractures were considered to be trauma related. Fractures in 
the pre-index time period were not distinguished as trauma or 
non-trauma, because collectively, fracture regardless of en-
ergy level increases risk for subsequent fractures.23 However, 
in the post-index period, only fractures that were non-trau-
matic (ie, NTFx) were examined.
In the post-index period, the first NTFx was examined. To 
be sure that the first NTFx event in the post-index period was 
indeed an incident fracture for those with a pre-index frac-
ture, it was required that the post-index period NTFx event 
was at a new site or there was a gap of at least 6 months from 
the previous NTFx event if at the same site. The 6-month 
gap requirement is a conservative approach compared to the 
3-month gap used in previous claims-based studies.15,18,19
Prevalence of fracture was examined in the pre-index pe-
riod, as measures were not taken to identify new-onset frac-
ture (ie, required another lookback period) and incidence of 
fracture was examined in the post-index period.
2.4 | Covariates
Covariates were selected based on their relevance to epilepsy 
or NTFx and availability and reliability in claims databases. 
Sociodemographic variables included age, sex, race, and US 
region of residence. Glucocorticoid medications and antisei-
zure medications were identified by at least one outpatient 
pharmacy claim for relevant medications anywhere in the 
12-month pre-index period to 2 weeks after the individual's 
index date, to capture individuals that may have been pre-
scribed these medications around the time of the osteoporosis 
medication prescription. A modified version of the validated 
Elixhauser comorbidity index was computed. The original 
Elixhauser comorbidity index includes a score (yes or no) for 
30 comorbidities.24 As there is some overlap with epilepsy, 
paralysis and other neurological disorders (which contain ep-
ilepsy codes) were omitted for this study. Co-occurring cere-
bral palsy is common among individuals with epilepsy and is 
strongly associated with skeletal fragility.9,22,25–29 Therefore, 
cerebral palsy was added as its own comorbidity to account 
for health and disease status, which made the total count of 
29 for the modified Elixhauser comorbidity index used in this 
study.
2.5 | Propensity-score matching
One-year incidence of NTFx is typically a rare outcome in 
research and may limit the interpretability of covariate-ad-
justed regression models when there is a need for adjustment 
of several covariates. Therefore, to account for confounders 
that may influence the associations of interest, the four com-
parison groups were each matched to the primary group of 
interest, EP new users, at a 1:1 matching ratio using a pro-
pensity score computed by the PSMATCH procedure in SAS 
version 9.4 (SAS Institute, Cary, NC, USA). We employed 
the greedy nearest neighbor method after randomizing the 
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order of the comparator groups, required a standard caliper 
of 0.25, and initially considered all covariates to create the 
propensity score. Balance in matching was examined and if 
not met, alternative approaches were taken.
2.6 | Statistical analysis
Descriptive characteristics were presented for each group; 
95% binomial confidence intervals (CIs) for the prevalence 
of pre-index fracture and incidence of post-index NTFx were 
calculated as the sample proportion  ±  the margin of error 
with a z-value of 1.96.30
To estimate the change in NTFx risk from pre- to post-in-
dex periods for each group, risk ratios (RRs) and 95% CIs were 
estimated. To determine if the change in NTFx risk was differ-
ent across groups, a difference-in-difference analysis was con-
ducted. Specifically, a generalized linear model with repeated 
measures and a log link function was used for NTFx as any site 
and then for each site separately. Each participant had two ob-
servations in the difference-in-difference analysis: presence of 
pre-index fracture and presence of post-index NTFx. The inter-
pretation of these analyses were focused on the relative change 
for the entire group, which is assessed by taking the ratio of 
the RR (RRR) from the groups being compared. The RRR is a 
numerical approximation of the time by exposure variable in-
teraction. In real world settings, the differences in pre-treatment 
profiles for those treated and not treated can impact interpreta-
tions regarding the effectiveness of a treatment (eg, osteoporo-
sis medication) on an outcome (eg, change in NTFx risk).15 By 
examining the longitudinal change in fracture prevalence using 
a within-person design, bias due to confounding is mitigated, as 
each group serves as their own internal control, making this an-
alytic approach a strength for addressing the research question.
2.7 | Sensitivity analysis
Antiseizure medication can lead to skeletal fragility through a 
variety of mechanisms.31 To determine if the change in pre-
index fracture to post-index NTFx differed by status of antisei-
zure medication exposure, unadjusted RRs for NTFx at any 
site were examined after stratifying each group by antiseizure 
medication exposure in the 12.5-month pre-index period. Site-
specific effects were not examined due to the small sample size.
Analyses were performed using SAS version 9.4 (SAS 
Institute, Cary, NC, USA).
3 |  RESULTS
Prior to matching, 9.1% of 52 398 adults ≥50 years of age with 
epilepsy that met all other eligibility criteria were prescribed an 
osteoporosis medication (n = 828 for new users, n = 3940 for 
consistent users), which was 1.69 times higher (95% CI = 1.64-
1.73) than the 5.4% of 4 329 365 adults without epilepsy.
Balanced matching without omitting any participant from 
the primary group of interest, EP new users, was not possible 
when US region of residence and race was included. Upon 
further examination, US region of residence was omitted 
and race was re-categorized as White, Black, and everything 
else, and successful matching for all groups was achieved. 
Descriptive characteristics from the pre-index period for all 
groups (n = 828/group) is presented in Table 1. Using the 
chi-square test, there were significant group differences for 
US region of residence (P < .001) and race when examined 
as the original categories (P = .005), but not for race when 
re-categorized (P =  .533) due to matching; no other group 
differences were observed. Approximately 96%-97% of the 
osteoporosis medication groups were prescribed an antire-
sorptive agent and the remaining 3%-4% were prescribed an 
anabolic agent.
3.1 | Prevalence of pre-index fracture and 
incidence of post-index NTFx
Notably, EP new users had a higher prevalence of pre-index 
fracture at any site compared to all comparison groups and 
pre-index fracture at each site compared to all comparison 
groups (all P < .05) except w/o EP new users (similar prev-
alence at each site) and EP consistent users for the lower 
extremities (similar prevalence; Table 2). In the post-index 
period, the differences were less pronounced, but EP users 
still had a higher incidence of NTFx at any site compared 
to all comparison groups (all P <  .05) except w/o EP new 
users (similar incidence). For site-specific effects in the post-
index period, EP new users had a similar NTFx incidence for 
each site compared to EP consistent users, higher incidence 
of NTFx at the vertebral column and hip compared to EP no 
users (both P < .05), and higher incidence of NTFx at the hip 
compared to w/o EP new and consistent users (both P < .05).
Because matching was not performed for US region of 
residence or race when examined as the full original catego-
rization, logistic regression models were developed to deter-
mine if these variables confounded the group comparisons. 
The results were the same as the unadjusted comparisons 
when adjusting for US region of residence or race (results 
not shown).
3.2 | Change in pre-index fracture to  
post-index NTFx
The change in pre-index fracture to post-index NTFx risk is 
visually presented in Figure 1 for any site and the unadjusted 
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RR is presented in Table 2. The unadjusted RR was signifi-
cantly lower for any site and each site for EP new users, EP 
consistent users (except for the upper extremities), and w/o 
EP new users, suggesting robust risk attenuation of NTFx 
for these groups. The unadjusted RR was non-significantly 
elevated for any site and each site (except for the hip) for EP 
no users.
The RRR for NTFx at any site was significantly lower 
for EP new users compared to EP no users (RRR = 0.35; 
95% CI = 0.23-0.54) and EP consistent users (RRR = 0.70; 
95% CI  =  0.51-0.97) suggesting a larger risk attenua-
tion of NTFx, but was similar compared to w/o EP new 
users (RRR  =  0.99; 95% CI  =  0.73-1.34; Table  3). The 
RRR for NTFx at any site was significantly lower for EP 
consistent users compared to EP no users (RRR  =  0.50; 
95% CI = 0.32-0.79), but was similar to w/o EP consistent 
users (RRR = 0.81; 95% CI = 0.55-1.17). The results were 
the same after adjusting the models for US region of resi-
dence and race (data not shown).
When risk attenuation of NTFx at specific sites was ex-
amined, the pattern of results was the same for NTFx of the 
vertebral column as NTFx at any site, but no significant 
findings were observed in NTFx risk attenuation of the hip 
across groups. Both EP new users and EP consistent users 
showed significant NTFx risk attenuation of the lower 
extremities compared to EP no users (both RRR  =  0.28, 
P < .05), but the change was similar between EP new and 
consistent users (RRR  =  1.01; 95% CI  =  0.42-2.44). EP 
T A B L E  1  Baseline descriptive characteristics of propensity matched participants (1:1, n = 828/group) by status of epilepsy (EP) and new, 
consistent, or no users of osteoporosis medication
EP new users EP consistent users EP no users w/o EP new users
w/o EP 
consistent users
% % % % %
Age, mean (SD) 69.9 (10.1) 69.6 (9.7) 70.1 (10.2) 70.5 (10.0) 70.3 (10.2)
50-64 y 31.4 32.7 31.5 29.1 31.0
65-79 y 47.6 48.0 46.5 48.0 45.8
≥80 y 21.0 19.3 22.0 23.0 23.2
Sex
Women 82.1 85.1 82.1 82.0 82.0
Men 17.9 14.9 17.9 18.0 18.0
Race
White 64.9 66.6 67.6 67.3 65.8
Black 7.3 5.7 6.0 5.6 4.7
Hispanic 11.1 10.8 9.2 12.7 12.1
Asian 2.8 4.0 2.1 2.9 5.6
Unknown/missing 14.0 13.0 15.1 11.6 11.8
US region
West 34.9 28.5 25.7 32.9 29.8
Midwest 13.9 18.0 20.7 15.5 17.0
South 36.8 35.0 39.1 40.7 40.5
Northeast 14.4 18.5 14.5 11.0 12.7
Elixhauser comorbidity index
Mean (SD) 4.4 (3.1) 4.4 (3.1) 4.3 (2.8) 4.5 (3.0) 4.3 (2.9)
Median (IQR) 4.0 (2.0-6.0) 4.0 (2.0-6.0) 4.0 (2.0-6.0) 4.0 (2.0-6.0) 4.0 (2.0-6.0)
Glucocorticoid 
medications
25.2 24.4 23.7 26.3 23.2
Antiseizure medications 64.3 66.7 65.6 64.3 64.6
Osteoporosis medication
Antiresorptive agents 96.6 97.1 0 95.7 97.3
Anabolic agents 3.4 2.9 0 4.3 2.7
Abbreviations: IQR, interquartile range; SD, standard deviation.
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new users had a significantly lower RRR for NTFx of the 
upper extremities compared to EP no users (RRR = 0.36; 
95% CI = 0.14-0.91). The results were the same after ad-
justing the models for US region of residence and race 
(data not shown).
3.3 | Sensitivity analysis
The prevalence of pre-index fracture and incidence of post-
index NTFx was higher for those exposed to antiseizure 
medication in the 12.5-month pre-index period for the os-
teoporosis medication groups, but only reached statistical 
significance for pre-index fracture for w/o EP consistent 
users (Table 4). The unadjusted RR was similar for those 
exposed and not exposed to antiseizure medication within 
each group except for EP consistent users, where those ex-
posed to antiseizure medication had a significantly lower 
RR (RR = 0.63; 95% CI = 0.44-0.91) but those not exposed 
did not have a significantly lower RR (RR  =  0.91; 95% 
CI = 0.50-1.65).
4 |  DISCUSSION
The findings from this study suggest that osteoporo-
sis medication is associated with a clinically meaningful 
12-month NTFx risk attenuation among adults with epilepsy, 
which mirrored that of the general population without epi-
lepsy. The beneficial effect of osteoporosis medication for 
adults with epilepsy was observed for all sites, including the 
T A B L E  2  Risk and unadjusted risk ratio (RR) of pre- and post-index fracture among propensity matched participants (1:1, n = 828/group) by 
status of epilepsy (EP) and new, consistent, or no users of osteoporosis medication
EP new users
EP consistent 
users EP no users w/o EP new users
w/o EP consistent 
users
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Pre-index period
Any site 26.1 (23.1, 29.1) 10.8 (8.6, 12.9) 4.7 (3.3, 6.2) 19.3 (16.6, 22.0) 8.1 (6.2, 9.9)
Vertebral column 13.7 (11.3, 16.0) 5.2 (3.7, 6.7) 1.3 (0.5, 2.1) 10.9 (8.7, 13.0) 4.7 (3.3, 6.2)
Hip 7.0 (5.3, 8.7) 3.5 (2.2, 4.8) 1.9 (1.0, 2.9) 4.0 (2.7, 5.3) 1.0 (0.3, 1.6)
Lower extremities 5.0 (3.5, 6.4) 2.8 (1.7, 3.9) 0.9 (0.2, 1.5) 4.0 (2.7, 5.3) 1.5 (0.6, 2.3)
Upper extremities 5.8 (4.2, 7.4) 2.1 (1.1, 3.0) 1.3 (0.5, 2.1) 3.7 (2.4, 5.0) 1.1 (0.4, 1.8)
Post-index period
Any site 12.8 (10.5, 15.1) 7.5 (5.7, 9.3) 6.5 (4.8, 8.2) 9.5 (7.5, 11.5) 7.0 (5.3, 8.7)
Vertebral column 4.8 (3.4, 6.3) 3.1 (2.0, 4.3) 2.3 (1.3, 3.3) 4.6 (3.2, 6.0) 3.6 (2.3, 4.9)
Hip 2.9 (1.8, 4.0) 1.6 (0.7, 2.4) 1.0 (0.3, 1.6) 0.9 (0.2, 1.5) 1.0 (0.3, 1.6)
Lower extremities 2.2 (1.2, 3.2) 1.2 (0.5, 2.0) 1.3 (0.5, 2.1) 1.5 (0.6, 2.3) 0.9 (0.2, 1.5)
Upper extremities 2.3 (1.3, 3.3) 1.3 (0.5, 2.1) 1.5 (0.6, 2.3) 1.8 (0.9, 2.7) 1.1 (0.4, 1.8)
RR (pre- to post-index) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Any site 0.49 (0.40, 0.61) 0.70 (0.51, 0.95) 1.39 (0.93, 2.07) 0.49 (0.38, 0.64) 0.87 (0.62, 1.21)
Vertebral column 0.35 (0.25, 0.50) 0.61 (0.38, 0.98) 1.73 (0.83, 3.61) 0.42 (0.29, 0.61) 0.77 (0.48, 1.23)
Hip 0.41 (0.26, 0.66) 0.45 (0.24, 0.86) 0.50 (0.22, 1.16) 0.21 (0.09, 0.48) 1.00 (0.38, 2.65)
 Lower extremities 0.44 (0.25, 0.76) 0.44 (0.21, 0.91) 1.57 (0.61, 4.03) 0.36 (0.19, 0.70) 0.58 (0.23, 1.47)
Upper extremities 0.40 (0.24, 0.67) 0.65 (0.31, 1.37) 1.09 (0.48, 2.46) 0.48 (0.26, 0.89) 1.00 (0.40, 2.51)
Abbreviations: CI, confidence interval.
F I G U R E  1  Unadjusted prevalence of pre-index fracture and 
incidence of post-index non-trauma fracture (and 95% confidence 
interval) at any site for propensity matched adults (1:1 matching 
ratio) by status of epilepsy (EP) and new, consistent, or no 
users of osteoporosis medication
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vertebral column, hip, lower extremities, and upper extremi-
ties. Furthermore, the effect of osteoporosis medication was 
not altered by exposure to antiseizure medication for adults 
with epilepsy who were new users of osteoporosis medica-
tion. It is important to note that causation cannot be derived 
from an observational study, especially for determining ef-
fectiveness of treatment due to a variety of factors, including 
unmeasured confounding. Furthermore, this observational 
study did not examine adverse events or side effects asso-
ciated with osteoporosis medication. Taken together, study 
findings provide real world evidence about the effectiveness 
of osteoporosis medication on site-specific NTFx risk at-
tenuation among a large privately insured cohort of adults 
≥50 years of age with epilepsy. However, prior to changing 
clinical practice and osteoporosis medication prescription, 
future studies are needed to determine safety and efficacy of 
osteoporosis medication in relation to the medical and phar-
macological complexities associated with epilepsy.
In this sample of privately insured adults ≥50  years of 
age, 9.1% of the epilepsy group was prescribed an osteo-
porosis medication. Although 1.69 times higher compared 
to the group without epilepsy, this is still not addressing 
the pharmacological needs to augment skeletal robustness 
for this population. Previous research suggests that one in 
five adults ≥18  years of age with epilepsy has a prevalent 
NTFx6 and three to four of five adults with epilepsy have low 
bone mineral density.3,4 It is important to note that a recent 
claims-based study using private insurance found that NTFx 
T A B L E  3  The ratio of the risk ratio (RRR) of pre- to post-index fracture among propensity matched participants (1:1, n = 828/group) by 
status of epilepsy (EP) and new, consistent, or no users of osteoporosis medication
Any site Vertebral column Hip Lower extremities
Upper 
extremities
RRR (95% CI) RRR (95% CI) RRR (95% CI) RRR (95% CI) RRR (95% CI)
EP new users vs EP no users 0.35 (0.23, 0.54) 0.21 (0.10, 0.44) 0.83 (0.22, 1.13) 0.28 (0.09, 0.83) 0.36 (0.14, 0.91)
EP consistent users vs EP no 
users
0.50 (0.32, 0.79) 0.35 (0.16, 0.77) 0.89 (0.33, 2.41) 0.28 (0.09, 0.90) 0.60 (0.21, 1.75)
EP new users vs EP consistent 
users
0.70 (0.51, 0.97) 0.58 (0.35, 0.97) 0.92 (0.45, 1.90) 1.01 (0.42, 2.44) 0.61 (0.25, 1.47)
New users, EP vs w/o EP 0.99 (0.73, 1.34) 0.84 (0.52, 1.35) 1.95 (0.77, 4.92) 1.20 (0.54, 2.70) 0.82 (0.39, 1.72)
Consistent users, EP vs w/o EP 0.81 (0.55, 1.17) 0.79 (0.46, 1.35) 0.45 (0.16, 1.24) 0.74 (0.25, 2.19) 0.65 (0.23, 1.85)
Abbreviation: CI, confidence interval.
T A B L E  4  Risk and unadjusted risk ratio (RR) of pre- and post-index fracture at any site by status of antiseizure medication (ASM) exposure, 
epilepsy (EP), and new, consistent, or no users of osteoporosis medication
EP new users EP consistent users EP no users w/o EP new users
w/o EP 
consistent users
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Pre-index period
ASM exposure
No 22.6 (17.9, 27.4) 7.6 (4.5, 10.7) 5.6 (2.9, 8.3) 19.3 (14.8, 23.8) 4.8 (2.3, 7.2)
Yes 28.0 (24.2, 31.8) 12.3 (9.6, 15.1) 4.2 (2.5, 5.9) 19.4 (16.0, 22.7) 9.9 (7.4, 12.4)
Post-index period
ASM exposure
No 11.5 (7.9, 15.1) 6.9 (3.9, 9.9) 7.7 (4.6, 10.8) 7.8 (4.7, 10.8) 4.4 (2.1, 6.8)
Yes 13.5 (10.6, 16.4) 7.8 (5.6, 10.0) 5.9 (3.9, 7.9) 10.5 (7.9, 13.1) 8.4 (6.1, 10.8)
RR (pre- to 
post-index) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
ASM exposure
No 0.51 (0.35, 0.74) 0.91 (0.50, 1.65) 1.38 (0.74, 2.56) 0.40 (0.26, 0.64) 0.93 (0.44, 1.94)
Yes 0.48 (0.38, 0.62) 0.63 (0.44, 0.91) 1.39 (0.83, 2.35) 0.54 (0.41, 0.74) 0.85 (0.58, 1.24)
Abbreviation: CI, confidence interval.
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is associated with an accelerated rate of mortality among 
adults with epilepsy (70% higher) and compared to adults 
without epilepsy (41% higher) before and after accounting 
for potential confounders.6 In that study,6 site-specific effects 
were examined. Although the hip was the most commonly 
fractured site (consistent with the current study for EP no 
users), it elicited a significant, although weaker, unadjusted 
and adjusted association with 12-month mortality for adults 
with epilepsy compared to other sites (adjusted hazard ratio 
[HR]=1.15; P <  .05). The lower extremities had the stron-
gest unadjusted and adjusted effect with 12-month mortal-
ity (adjusted HR = 1.92), followed by the upper extremities 
(adjusted HR  =  1.79) and the vertebral column (adjusted 
HR = 1.30) (all P < .05). Although osteoporosis medication 
is prescribed to reduce the risk of NTFx, it is associated with 
lower risk of mortality.32 This additional benefit is important 
for adults with epilepsy given the excessive burden of prema-
ture mortality10-13 that may be exacerbated by NTFx.6
In the current study, when examining group specific 
changes (ie, RR), significant risk attenuation of NTFx of the 
vertebral column, hip, lower extremities, and upper extrem-
ities was observed for adults with epilepsy that were new 
users, whereas the same was observed for consistent users 
with epilepsy except for the upper extremities. Adults with 
epilepsy who were not prescribed osteoporosis medication is 
a useful group to examine what would happen to fracture risk 
without any intervention. This group exhibited an increase in 
NTFx risk for the vertebral column, lower extremities, and 
upper extremities, but a decrease in NTFx risk of the hip, 
although all these changes were not statistically significant.
When comparing the RRR, or the extent of change in 
NTFx risk across groups, study findings suggest that newly 
prescribed osteoporosis medication is associated with a ro-
bust decrease in NTFx risk in epilepsy and consistent users 
with epilepsy still exhibit a clinically meaningful NTFx risk 
attenuation compared to adults with epilepsy who were not 
prescribed osteoporosis medication. However, because it was 
not possible to determine chronicity of osteoporosis medica-
tion exposure, results from this group should be interpreted 
with caution.
For site-specific effects, new users with epilepsy had a 
larger NTFx risk attenuation at all sites compared to adults 
with epilepsy who were not prescribed an osteoporosis med-
ication except for the hip. Of interest, although the change 
in NTFx risk of the vertebral column, lower extremities, and 
upper extremities for new users with epilepsy mirrored that 
of the new users without epilepsy, the change in NTFx risk 
of the hip was 95% higher for new users with vs without ep-
ilepsy (RRR = 1.95). Although not statistically significant, 
this finding suggests that the NTFx risk attenuation associ-
ated with new osteoporosis medication use for this important 
fracture site is approximately half for adults with vs without 
epilepsy. This finding should be interpreted with caution as it 
is possible that prescription of osteoporosis medication may 
have been driven by the type and location of fracture, thus 
leading to bias from unmeasured confounding.
The causes and pathophysiological mechanisms leading 
to fractures in epilepsy are complex and multifactorial. For 
example, seizures account for a considerable portion of frac-
tures (~25%), but the burden of fracture is still elevated for 
patients with vs without epilepsy when excluding seizure- 
related fractures.33,34 Antiseizure medications are commonly 
prescribed to individuals with epilepsy and are well-estab-
lished risk factors for skeletal fragility,35 possibly due to a 
variety of direct and indirect effects on skeletal metabolism, 
such as altered vitamin D and calcium metabolism, neuro-
logical side effects (eg, gait instability, falls), endocrine dis-
ruption, and altered bone turnover.31 In the current study, 
the findings were similar for new users with epilepsy when 
stratified by 12.5-month exposure to antiseizure medication. 
Interpretations regarding the association with antiseizure 
medication for the other groups should be done so with cau-
tion, as this study was designed to match based on several 
covariates to EP new users, which included antiseizure med-
ication. Therefore, although the EP new user group can be 
considered representative of this privately insured sample, 
the other groups may not, especially for the groups without 
epilepsy. Future studies are needed to determine the efficacy 
of osteoporosis medication based on the varying pathophys-
iology leading to skeletal fragility, and if different classes of 
osteoporosis medication (eg, bisphosphonates, RANKL in-
hibitor) elicits differential skeletal effects among adults with 
epilepsy.
In addition to the observational cohort design lead-
ing to potential bias from unmeasured confounding, this 
study has other limitations. First, information regarding 
the type, etiology, or time since diagnosis of epilepsy was 
not possible. Furthermore, accuracy of identifying epi-
lepsy cases in administrative claims data can be less than 
ideal. Algorithms to identify epilepsy that rely solely on 
electromyography or magnetic resonance imaging tend to 
have low positive predictive value, whereas the codes used 
in the current study tend to have higher positive predic-
tive value.36,37 Furthermore, the number of occurrences 
of the claim with a respective epilepsy code further en-
hances the positive predictive value37; for this study, the 
positive predictive value is estimated to be ~70%-100% 
based on previous validation studies.17,36,38 Nevertheless, 
it is possible that some cases were misclassified and the 
conclusions drawn from this study should be made with 
caution. Second, chronicity of osteoporosis medication 
or antiseizure medication was not possible. Third, claims 
data provide a date of when a prescription was ordered and 
filled, but not if the patient took the medication or adhered 
to the medication dosage and timing. Furthermore, anti-
seizure medications alone are unable to classify epilepsy 
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status as these medications can be used clinically to treat 
or manage other conditions, such as neuropathic pain, 
mood disorders, and other central nervous system disor-
ders. However, it is possible that some individuals in the 
without epilepsy groups were misclassified, thus dilut-
ing the comparisons between epilepsy and non-epilepsy 
groups. Fourth, there may have been additional interven-
tion or counseling around the time of the first osteoporosis 
medication prescription. For example, health care provid-
ers may have talked with the patient or provided informa-
tion leading to changes in nutrition, smoking, alcohol use, 
avoidance of risky behaviors, exercise, and rehabilitation. 
This type of intervention(s) would be less likely to occur 
for the EP no users group. However, because new and con-
sistent users were compared by status of epilepsy (eg, new 
users with vs without epilepsy), most comparisons were 
unaffected by this potential issue. Fifth, over-the-counter 
medications cannot be accounted for using claims data, 
such as vitamin and/or mineral supplements. Finally, this 
study did not examine specific medications or classes of 
antiseizure medication, such as enzyme-inducing agents, 
which may have a differential effect on skeletal fragility. 
Future studies are needed to address this knowledge gap.
In conclusion, osteoporosis medication among privately 
insured adults ≥50 years of age with epilepsy is associated 
with a clinically meaningful risk attenuation of NTFx, espe-
cially for treatment-naive individuals, which mirrored that 
of adults without epilepsy. For treatment-naive adults with 
epilepsy, the beneficial effect was not influenced by a recent 
12.5-month exposure to antiseizure medication and was ob-
served at the vertebral column, hip, lower extremities, and 
upper extremities. Future studies are needed to determine 
safety, efficacy, timing, and dosing of osteoporosis medica-
tion to reduce NTFx risk for all adults with epilepsy.
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